DGAP-News: CURAXIS' MEMRYTE NAMED ONE OF THE TOP 100 DRUGS IN DEVELOPMENT TODAY BY R&D DIRECTIONS
(firmenpresse) - DGAP-News: Curaxis Pharmaceutical Corp. / Key word(s): Forecast/Market
Report
CURAXIS' MEMRYTE NAMED ONE OF THE TOP 100 DRUGS IN DEVELOPMENT TODAY
BY R&D DIRECTIONS
09.05.2011 / 15:03
---------------------------------------------------------------------
U.S. Contact:
Curaxis Pharmaceutical Corp.
David Corcoran
Email: dcorcoran(at)curaxispharma.com
www.curaxispharma.com
Europe Contact:
Continental Advisors SA
Andreea Porcelli
Email: andreea.porcelli(at)contiadvisors.com
www.contiadvisors.com
CURAXIS' MEMRYTE NAMED ONE OF THE TOP 100 DRUGS
IN DEVELOPMENT TODAY BY R&D DIRECTIONS
SWAMPSCOTT, MA - MAY 9, 2011 - Curaxis Pharmaceutical Corporation ('8CX')
('Curaxis' or the 'Company') announced that its lead drug hormone product
for Alzheimer's disease, Memryte, has been named by the editors of R&D
Directions magazine as one of the top '100 Great Investigational Drugs in
Development' today. In its tenth annual list of promising clinical
compounds, R&D Directions cited Curaxis' drug that addresses the
pathologies of Alzheimer's disease through multiple pathways, including
beta amyloid, tau phosphorylation, inflammation and aberrant cell cycling,
as a unique clinical approach in targeting the brain disorder.
'We are honored to be recognized by industry analysts and editors and are
delighted by the high-level interest in our science and lead drug
candidate,' said Patrick S. Smith, Chief Executive Officer of Curaxis.
'This further demonstrates the progress we are making and reflects the
potential for Memryte to be the first disease modifying treatment for
Alzheimer's disease. It is a very exciting time for Curaxis as we plan to
begin phase IIB clinical trials in the second half of 2011 and we
appreciate this acknowledgement of our work to find a treatment that halts
the progression of this devastating disease.'
R&D Directions is a leading publication for the pharmaceutical industry and
is focused on the progress of drugs advancing through research and
development. The March 2011 issue profiles 100 investigational drugs and
reviews hundreds of others from Phase I through Phase III. The list
reflects the current interests of industry observers and analysts.
Currently, thousands of compounds are being developed at large and small
companies throughout the world. To be included in R&D Directions' top 100
list, substances had to show potential in a major or growing therapeutic
area and be active in development. Many of the compounds on the list
address unmet medical needs and several drugs that have made the list in
the past eventually go on to receive FDA approval.
About Curaxis
Curaxis is an emerging specialty pharmaceutical company with a hormone drug
product candidate for the treatment of Alzheimer's disease and multiple
cancers. Curaxis' therapeutic platform is based on the hypothesis that
many diseases of aging may be caused by age-related changes in the function
of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a
hormonal endocrine feedback loop that controls development, reproduction
and aging in animals. This drug development platform is built on the
premise that hormones associated with this feedback loop are beneficial
early in life, when they promote growth and development, but are harmful
later in life when the mechanism for feedback is compromised, thereby
leading to disease processes, including pathologies associated with
Alzheimer's disease and various cancers.
Notice Regarding Forward Looking Statements
This press release includes certain 'Forward-Looking Statements' within the
meaning of section 21E of the Securities Exchange Act of 1934, as amended.
All statements regarding potential results and future plans and objectives
of Curaxis Pharmaceutical Corporation are forward-looking statements that
involve various risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and future
events could differ materially from those anticipated in such statements.
Important factors that could cause actual results to differ materially from
our expectations include, but are not limited to, those factors that are
disclosed under the heading 'Risk Factors' and elsewhere in our documents
filed from time to time with the U.S. Securities and Exchange Commission.
Other risk factors may include, but are not limited to, fluctuation in
quarterly results, and increased competition in our operations, our ability
to continue operations as scheduled, and our ability to protect the
proprietary technology we use. Further, the Company operates in an
industry sector where securities values are highly volatile and may be
influenced by economic and other factors beyond the Company's control, such
as announcements by competitors and service providers.
The contents of this press release are presented as a general overview of
the Company. It is intended only to contain general information regarding
the Company and its business and does not purport to provide complete
disclosure or analysis of all matters, which may be relevant to a decision
to make an investment, including all risk factors or similar
considerations. Although the information is believed current as of the
date herein, the information may be subject to change, amendment or
supplementation, and the Company does not expect, and assumes no
obligation, to update or otherwise revise the information herein.
# # #
End of Corporate News
---------------------------------------------------------------------
09.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
123619 09.05.2011
Datum: 09.05.2011 - 15:03 Uhr
Sprache: Deutsch
News-ID 33997
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: CURAXIS' MEMRYTE NAMED ONE OF THE TOP 100 DRUGS IN DEVELOPMENT TODAY BY R&D DIRECTIONS"
steht unter der journalistisch-redaktionellen Verantwortung von
Curaxis Pharmaceutical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
